A medical researcher alleged that American Home Product Corp. paid for promoting its drug Dexfenfluramine or Redux, which constitutes the Fen part of miracle weight loss drug Fen-Phen. It said in his statement that he would not have written an article promoting fen-phen, if he would have been aware of the fact that the manufacturing company of Dexfenfluramine had paid for a favoring article. He also blamed that the article was also edited by American Home Products Corp in such a way that it promoted its drug Redux, which contains Dexfenfluramine.

Redux (dexfenfluramine) is an oral medication. It is used for treatment of obesity. It belongs to serotonin reuptake inhibitor and releasing agent group of drugs. Redux is actually dexfenfluramine hydrochloride. It is administered with low calorie diet for weight reduction and management. It was approved by U.S. Food and Drug administration in 1990 to be used for weight loss. Later it was linked with several cardio vascular diseases including primary pulmonary hypertension. FDA cancelled its approval in 1997, due to safety concerns. It was approved as an appetite suppressant in the obesity management by FDA.

The writer of that article is Dr. Albert Stunkard, and article was published in the American Journal of Medicine in February 1996. He called this act as misleading and said that it made him uneasy, when he came to knew the fact.

A lawsuit also claimed that Wyeth-Ayerst Laboratories, a subsidiary of American Home Products Corp. and manufacturer of Dexfenfluramine hired ghostwriters for favoring articles. The lawsuit blamed that the company paid writers to write articles promoting obesity treatment using their drug. It also used prominent researchers such as Stunkard to publish the works under their names.

The lawsuit stated that the pharmaceutical company Wyeth was the manufacturer of Fen part of drug Fen-Phen and it hid the risks associated with use of this drug. Later FDA recall of Dexfenfluramine and Fenfluramine had proved danger of these drugs. It accused company of playing down or removing descriptions of side effects from different articles written on these drugs. Out of ten Wyeth paid articles were published in Medical Journals, before its recall in September 1997. The drug was recalled after studies linked it to heart valve damage and severe lung diseases. Wyeth was forced to cancel other eight articles planned for publication.

Dr. Albert Stunkard was a Medical researcher at University of Pennsylvania. Wyeth said in a statement that it is a common practice in industry to publish favoring articles. Wyeth is not the only one to do so. But they dismissed the idea that they cheat researchers for doing so. They maintained that author had the last say in this regard.

Lawsuit claimed that Wyeth and its subsidiary hired Excerpta Medica, Inc., to write the 10 articles. Excerpta Medica Inc is based in Belle Mead, N.J. They had plans to submit most of the papers to medical journals published by its owner company Reed Elsevier Plc. Two of the articles got published before recall of Dexfenfluramine and other eight were cancelled after recall of the drug.